Metabolism Supplement Guide

A metabolism supplement is a capsule, powder or drink sold on the idea that it makes the body spend more energy, absorb less of what is eaten, or want less food. Those are three completely different mechanisms and almost every product in the category mixes them without saying which it is relying on.

The distinction matters because the evidence differs enormously between them. Energy expenditure can be measured directly in a chamber over twenty-four hours. Absorption can be measured from what comes out. Appetite is measured by asking people how hungry they are, which is the softest of the three and the one most often cited.

Four claims, four evidence bases. A bottle mixing all four is borrowing credibility from the strongest one.

The fourth row is where most of the category's marketing lives, and it is worth recognising on sight. A sentence about what a compound does to a fat cell is a sentence about a dish of cells, and the distance between that and a person is the whole problem.

Green coffee bean extract is unroasted coffee, and the compound it is standardised for is chlorogenic acid. It is the ingredient whose evidence has the clearest shape in this category, and that shape is a threshold rather than a curve.

A 2023 systematic review and meta-analysis pooled the randomised trials and reported a 1.30 kg advantage over placebo, with a confidence interval that did not cross zero and no detectable publication bias. That result appeared at chlorogenic acid intakes of 500 mg a day and above. Below it, nothing.

A separate dose-response meta-analysis came at the same question from the other direction and found no association between dose and any anthropometric change, which is the honest counterweight. The 2011 systematic review had already noted that the trials were small, short and mostly poorly reported.

There is one more thing a reader of this literature should know: the trial that made green coffee famous has been retracted. It is still cited in marketing copy across this category, years after its withdrawal.

Garcinia is standardised for hydroxycitric acid, and there are two entirely different conversations about it. Whether it works is one. Whether it is safe is the other. They have different evidence bases and mixing them produces nonsense in both directions.

On whether it works: a randomised trial published in JAMA gave 1,500 mg of hydroxycitric acid a day for twelve weeks and found no advantage over placebo on fat mass. A pooled analysis of twelve trials found a small short-term difference of borderline significance. The appetite work is split down the middle: one two-week crossover found reduced energy intake, while a twelve-week trial in 89 women and a second crossover found nothing.

On whether it is safe, the picture is sharper and it does not depend on the efficacy question at all. The national drug-induced liver injury series adjudicated twenty-two cases with high confidence out of 1,418 enrolled patients. Five were garcinia alone; sixteen were garcinia combined with green tea. Onset ran from 13 to 223 days with a median of 51, ninety-one per cent were hospitalised, one patient received a transplant and one died.

A 2025 review of the hepatotoxicity evidence and a transplant case report set out the same picture in more detail. None of it says garcinia will injure a given person, and all of it says the combination with green tea is the pattern worth knowing about.

Green tea extract is the ingredient in this category with the most credible mechanism, and the number attached to it is worth quoting precisely. A 1999 trial measured twenty-four hour energy expenditure in a respiratory chamber and found a 4 per cent increase on a green tea extract delivering 270 mg of EGCG a day alongside caffeine.

The same trial ran a caffeine-only arm at 150 mg a day and reported no effect on energy expenditure, respiratory quotient, urinary nitrogen or catecholamines. That comparison is the most useful single result in this whole category, because it says the catechins were doing something the caffeine on its own was not.

Carried forward, a twelve-week trial using 625 mg of catechins a day found greater abdominal fat loss than control, with a protocol that also required 180 minutes a week of supervised exercise. A meta-analysis of energy expenditure confirmed a modest effect for catechin and caffeine mixtures, and the Cochrane review concluded the weight effect across trials was small and not clinically important.

The price of the mechanism is the one the United States Pharmacopeia expert panel documented: case reports of liver injury clustering between roughly 140 mg and 1,000 mg of EGCG a day, with absorption sharply higher when a concentrated dose is taken fasting. One clinical trial was stopped early for liver signals at a high dose.

Raspberry ketone is the aroma compound in raspberries and a long-established food flavouring. It became a weight supplement ingredient after television coverage, and the research record behind it has never caught up with the reputation.

A 2022 review of what is known about it describes the record accurately: cell culture work on lipolysis and adiponectin, rodent feeding studies, and biosynthesis papers. A controlled feeding study in mice found it failed to reduce adiposity beyond the effect of eating less.

The one human trial containing it was a multi-ingredient product tested alongside an exercise and diet programme, which cannot attribute any result to one component. A cardiology case report raised a question about coronary vasospasm in a user of a raspberry ketone product, and a single case report is a question rather than an answer.

A reader can hold two ideas at once here. There is no evidence raspberry ketone does anything useful in people, and there is no evidence it is dangerous at food or supplement amounts. What there is, is an absence of the human trial that would settle either.

Four habits separate a useful result from a decorative one, and none of them requires any technical training.

Dietary supplements in the United States are not approved before sale, and a label may not say a product treats or prevents anything. What is left is a narrow band of permitted structure and function language, always accompanied by the statement that the claims have not been evaluated by the Food and Drug Administration.

This is why the sentence on a bottle is almost always weaker than the sentence on the page selling it. The bottle is a regulated surface and the sales page is much less so. Guidance from the Federal Trade Commission covers what a seller may say in advertising, and the gap between the two surfaces is where most of this category's exaggeration lives.

The practical habit that follows is simple. Read the bottle rather than the page. If a claim appears on a website and not on the label, it belongs to whoever wrote the website.

Five conclusions come out of the literature above, and they apply to any bottle in this category rather than to one of them.

Set against that, the product this website sells prints an amount for all five of its actives and a standardisation for three, which makes the comparison possible rather than hypothetical. The scorecard runs it through seven checks and it does not pass all of them.